Biomarker and molecular testing to help oncologists match patients with the best cancer treatment can be challenging in the community oncology setting and in underserved communities. At present, patients with cancer in racially or ethnicly underserved communities are not receiving biomarker testing at the same rate as White patientin communities with greater access to care. Barriers to testing include insurance restrictions, conflicting guidelines, and the reliance of community oncologists on single-gene testing instead of the multi-gene panels that are used more often by academic oncologists. In the multidisciplinary setting of community oncology, healthcare professionals (HCPs) would benefit from education on best practice models that provide cost-effective molecular testing services for the undertested underserved population, especially given that more recently U.S. Food and Drug Administration (FDA)-approved treatments require biomarker testing.
In this CME Outfitters live symposium, expert faculty will evaluate the latest biomarker testing strategies in prostrate, bladder, and lung cancer; discuss how to integrate all members of the interdisciplinary care team in community oncology settings; identify root causes of health inequity in cancer care; and review strategies to address barriers that prevent the uptake of biomarker testing services in cancer care management.
